Paclitaxel induced chronic fibrosing interstitial pneumonitis: a case report and review of the literature

  • Renata Ferrarotto | renataf@hotmail.com Hospital Sirio Libanes, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Guilherme Schetino Hospital Sirio Libanes, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Daniela Freitas Hospital Sirio Libanes, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Vera Capelozzi Hospital Sirio Libanes, Universidade de Sao Paulo, Sao Paulo, Brazil.
  • Paulo M. Hoff Hospital Sirio Libanes, Universidade de Sao Paulo, Sao Paulo Instituto do Cancer do Estado de Sao Paulo, Universidade de Sao Paulo, Sao Paulo, Brazil.

Abstract

Pulmonary toxicity is rarely associated with paclitaxel chemotherapy and its mechanism is not well known. This report describes one patient with pancreatic adenocarcinoma, metastatic neuroendocrine low-grade pancreatic tumor, and a concomitant stage I non-small cell lung cancer (NSCLC), who also developed life-threatening paclitaxel-induced chronic fibrosing interstitial pneumonitis. Giving the gravity of the condition and the not-wellestablished treatment, physicians should be aware of the possibility of chronic fibrosing interstitial lung disease during the course of paclitaxel containing regimens in patients who present with respiratory symptoms.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-05
Info
Issue
Section
Reviews
Keywords:
Paclitaxel - Chronic fibrosing interstitial pneumonitis - Unclassified interstitial fibrosis
Statistics
  • Abstract views: 1289

  • FULL TEXT: 170
How to Cite
Ferrarotto, R., Schetino, G., Freitas, D., Capelozzi, V., & Hoff, P. M. (2011). Paclitaxel induced chronic fibrosing interstitial pneumonitis: a case report and review of the literature. Oncology Reviews, 4(2), 101-106. https://doi.org/10.4081/oncol.2010.53